Sales rose 12% to 13.44 billion euros on the continued strength of its anti-inflammatory drug Dupixent and sales in its pharma segment, which offset currency headwinds. Analysts expected business ...

Hindustan Unilever Ltd (HUL) announces the retirement of Dev Bajpai, Executive Director, Legal & Corporate Affairs, effective ...

US private equity firm Clayton Dubilier & Rice thought it had a deal to buy Sanofi’s consumer business. Losing bidder PAI ...

After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

France will take a stake in Sanofi's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on ...

Sanofi & Orano join forces to accelerate the development of develop next-generation radioligand medicines: Paris Friday, October 18, 2024, 10:00 Hrs [IST] Sanofi and Orano Med, a ...

Investors often monitor insider buying activity to assess whether company leadership has confidence in their own stock's ...

Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, . Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology ...

Exscientia plc today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments.

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...